The Novo Nordisk Foundation and its investment company Novo Holdings welcome the opportunity to respond to the European Commission's Call for Evidence on the European Biotech Act. Advancing biotech capabilities is essential for positioning the EU at the forefront of technology, fostering growth in sectors crucial for sustainable socioeconomic development and security.
NNF
Novo Nordisk Foundation
NGO · Denmark · EU Transparency Register 097928945982-83
4
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
4
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #358 by legislative files engaged, a count of participation, not a measure of influence.
4
declared lobbying FTE
self-declared
–
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2022
in the register since
Declares membership of
- NNF is member of the following organisations:
- Bio-based Industry Consortium
- Philanthropy Europe Association
- European Food Forum
- and Contributing partner of EDCTP3 call(s)
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Head office
- Hellerup, Denmark
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Novo in PolicySpeak: request access →
Work at Novo Nordisk Foundation? so we know who speaks for it.
Their record over time
Novo Nordisk Foundation filed 4 positions between 30 Oct 2023 and 23 Sept 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 4 times.
2023 · 1 filed2025 · 1 filed2026 · 2 filed
What they argued
Biotechnology is a strategic enabler of Europes competitiveness, sustainability, and resilience. Despite strong scientific capabilities, Europe continues to lag in translating research into industrial scale and market deployment, held back by regulatory complexity, limited biomanufacturing capacity, weak market demand, and investment gaps.
The Novo Nordisk Foundation and its investment company Novo Holdings welcome the proposal for a regulation from the European Commission for plants produced by certain new genomic techniques (NGTs). The proposal is a chance to create a forward-looking regulatory framework that promotes innovation and adapts to the scientific progress.
Novo Nordisk Foundation response to the Call for Evidence on the revision of the European Institute of Innovation and Technology (EIT) Regulation and Strategic Innovation Agenda The Novo Nordisk Foundation welcomes the revision of the EIT Regulation and Strategic Innovation Agenda.
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Novo Nordisk Foundation next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 98.
Is this your organization?
Everything on this page comes from Novo Nordisk Foundation’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.